Amundi Has $550,000 Stake in STAAR Surgical (NASDAQ:STAA)

Amundi boosted its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 174.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,785 shares of the medical instruments supplier's stock after buying an additional 15,128 shares during the quarter. Amundi's holdings in STAAR Surgical were worth $550,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier's stock worth $7,978,000 after acquiring an additional 172,779 shares during the last quarter. American Capital Management Inc. raised its holdings in STAAR Surgical by 42.9% during the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier's stock worth $19,051,000 after purchasing an additional 154,037 shares during the last quarter. KBC Group NV lifted its position in STAAR Surgical by 5,700.9% during the 4th quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier's stock valued at $2,346,000 after purchasing an additional 94,920 shares during the period. Barclays PLC boosted its stake in shares of STAAR Surgical by 349.4% in the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier's stock valued at $3,406,000 after purchasing an additional 71,301 shares during the last quarter. Finally, Polar Asset Management Partners Inc. boosted its stake in shares of STAAR Surgical by 44.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier's stock valued at $6,271,000 after purchasing an additional 51,800 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

STAA has been the topic of several analyst reports. Stephens restated an "equal weight" rating and issued a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. William Blair cut shares of STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Stifel Nicolaus reduced their price target on STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Mizuho downgraded STAAR Surgical from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. Finally, Jefferies Financial Group lowered STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $25.29.

STAAR Surgical Trading Up 0.3 %

Shares of NASDAQ STAA traded up $0.05 during mid-day trading on Monday, reaching $17.77. 880,160 shares of the company's stock were exchanged, compared to its average volume of 765,994. The business has a fifty day simple moving average of $19.87 and a 200 day simple moving average of $25.62. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68. The firm has a market capitalization of $876.51 million, a price-to-earnings ratio of -43.34 and a beta of 0.66.

Insider Activity

In other news, major shareholder Broadwood Partners, L.P. purchased 108,720 shares of the business's stock in a transaction dated Thursday, March 20th. The shares were bought at an average cost of $17.96 per share, for a total transaction of $1,952,611.20. Following the completion of the acquisition, the insider now directly owns 12,182,995 shares in the company, valued at approximately $218,806,590.20. This trade represents a 0.90 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 1,036,187 shares of company stock worth $17,239,548 over the last quarter. 1.00% of the stock is currently owned by company insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.